Foxchart.com
Supernus Pharmaceuticals, Inc. (SUPN)
51.775  0.325 (0.63%)  01-14 13:34
Open: 51.23
High: 52.16
Low: 50.93
Volume: 482,480
Market Cap: 2,898(M)
PE Ratio: -152.28
Exchange: NASDAQ Global Market
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell buy
Resistance 2: 61.32
Resistance 1: 52.50
Pivot price: 50.83
Support 1: 48.09
Support 2: 45.36
52w High: 57.65
52w Low: 29.16
Watchlist
SUPN0 (0%)
MSFT0 (0%)
TWTR0 (0%)
BAC0 (0%)
AMZN0 (0%)
FB0 (0%)
Zoom in Zoom out
Draw lines
Horizontal lines
Parallel lines
Fibonacci lines
Remove studies
Shot and share

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Financials
EPS -0.340
Book Value 18.380
PEG Ratio 0.00
Gross Profit 10.562
Profit Margin (%) -2.80
Operating Margin (%) 4.41
Return on Assets (ttm) 1.5
Return on Equity (ttm) -1.9
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
×
Share on Facebook Tweet this page

Foxchart international:  |  United States  |  Canada  |  United Kingdom  |  Australia  |  New Zealand  |  Singapore  |  India

©Foxchart.com All Rights Reserved. Foxchart.com | United States NYSE NASDAQ AMEX stock markets, stock quotes and stock technical analysis charts. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither Foxchart.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX